NCT03307564View on ClinicalTrials.gov

Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Pancreatic Adenocarcinoma
Interventions
DEVICE

TraceIT tissue marker injection

The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Augmenix, Inc.
All Listed Sponsors
collaborator

Augmenix, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03307564 - Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter